Literature DB >> 11752163

Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.

Patrick R Harrington1, Boyd Yount, Robert E Johnston, Nancy Davis, Christine Moe, Ralph S Baric.   

Abstract

Norwalk-like viruses (NLVs) are a diverse group of single-stranded, nonenveloped, positive-polarity RNA viruses and are the leading cause of epidemic acute gastroenteritis in the United States. In this study, the major capsid gene of Norwalk virus, the prototype NLV, has been cloned and expressed in mammalian cells using a Venezuelan equine encephalitis (VEE) replicon expression system. Upon infection of baby hamster kidney (BHK) cells with VEE replicon particles (VRPs), the Norwalk virus capsid proteins self-assemble to generate high titers of Norwalk virus-like particles (VLPs) that are morphologically and antigenically analogous to wild-type Norwalk virus. Mice inoculated subcutaneously with VRPs expressing the Norwalk virus capsid protein (VRP-NV1) developed systemic and mucosal immune responses to Norwalk VLPs, as well as heterotypic antibody responses to the major capsid protein from another genogroup I NLV strain (NCFL) isolated from a recent outbreak. A second Norwalk virus capsid clone (NV2) containing three amino acid codon mutations from the NV1 clone was also expressed using VEE replicons (VRP-NV2), but upon infection of BHK cells failed to confer VLP self-assembly. Mice inoculated with VRP-NV2 elicited reduced systemic and mucosal immune responses to Norwalk VLPs, demonstrating the importance and potential utility of endogenous VLP presentation for maximum immune induction. Inoculation with either VRP-NV1 or VRP-NV2 resulted in serum antibody responses far superior to the induction in mice dosed orally with VLPs that were prepared using the VEE-NV1 replicon construct, a regimen similar to current models for NLV vaccination. Expression of NLV VLPs in mammalian cells offers a powerful approach for the design of novel NLV vaccines, either alone or in combination with current vaccination models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752163      PMCID: PMC136807          DOI: 10.1128/jvi.76.2.730-742.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Genetic polymorphism across regions of the three open reading frames of "Norwalk-like viruses".

Authors:  J Vinjé; J Green; D C Lewis; C I Gallimore; D W Brown; M P Koopmans
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

2.  Posttranslational side chain modification of a viral epitope results in diminished recognition by specific T cells.

Authors:  J K Larson; L Otvos; H C Ertl
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

3.  Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein.

Authors:  X Jiang; M Wang; D Y Graham; M K Estes
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

4.  Structure of O-glycosidically linked oligosaccharides synthesized by the insect cell line Sf9.

Authors:  D R Thomsen; L E Post; A P Elhammer
Journal:  J Cell Biochem       Date:  1990-05       Impact factor: 4.429

5.  Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone.

Authors:  N L Davis; N Powell; G F Greenwald; L V Willis; B J Johnson; J F Smith; R E Johnston
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

6.  Sequence and genomic organization of Norwalk virus.

Authors:  X Jiang; M Wang; K Wang; M K Estes
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

7.  Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults.

Authors:  P C Johnson; J J Mathewson; H L DuPont; H B Greenberg
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

8.  Altered phosphorylation pattern of simian virus 40 T antigen expressed in insect cells by using a baculovirus vector.

Authors:  A Höss; I Moarefi; K H Scheidtmann; L J Cisek; J L Corden; I Dornreiter; A K Arthur; E Fanning
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

9.  Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations.

Authors:  K Y Green; J F Lew; X Jiang; A Z Kapikian; M K Estes
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

10.  Norwalk-like viral gastroenteritis outbreak in U.S. Army trainees.

Authors:  M K Arness; B H Feighner; M L Canham; D N Taylor; S S Monroe; T J Cieslak; E L Hoedebecke; C S Polyak; J C Cuthie; R L Fankhauser; C D Humphrey; T L Barker; C D Jenkins; D R Skillman
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

View more
  40 in total

1.  High-resolution x-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain.

Authors:  Stefan Taube; John R Rubin; Umesh Katpally; Thomas J Smith; Ann Kendall; Jeanne A Stuckey; Christiane E Wobus
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

2.  Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.

Authors:  Daniel R Tonkin; Alan Whitmore; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2012-04-21       Impact factor: 3.641

3.  Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects.

Authors:  Jesica Swanstrom; Lisa C Lindesmith; Eric F Donaldson; Boyd Yount; Ralph S Baric
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

4.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

5.  Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.

Authors:  Joseph M Thompson; Alan C Whitmore; Herman F Staats; Robert E Johnston
Journal:  Vaccine       Date:  2008-06-09       Impact factor: 3.641

6.  Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs.

Authors:  Amy C Sims; Ralph S Baric; Boyd Yount; Susan E Burkett; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice.

Authors:  Patrick R Harrington; Lisa Lindesmith; Boyd Yount; Christine L Moe; Ralph S Baric
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 8.  Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Authors:  Ming Tan; Xi Jiang
Journal:  Nanomedicine (Lond)       Date:  2012-06       Impact factor: 5.307

9.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.

Authors:  Joseph M Thompson; Michael G Nicholson; Alan C Whitmore; Melodie Zamora; Ande West; Akiko Iwasaki; Herman F Staats; Robert E Johnston
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.